How to Start Olanzapine
Begin olanzapine at 5–10 mg once daily (typically at bedtime), with a target dose of 10 mg/day reached within several days; doses above 10 mg/day rarely provide additional benefit and increase side effects. 1
Initial Dosing for Adults with Schizophrenia or Bipolar Disorder
- Start with 5–10 mg once daily without regard to meals, generally administered at bedtime to leverage sedative properties. 1
- Target 10 mg/day within several days of initiation, as this dose demonstrates optimal efficacy in clinical trials. 1
- Doses above 10 mg/day were not more efficacious than 10 mg/day in schizophrenia trials, so routine escalation beyond this target is not recommended. 1
- Maximum approved dose is 20 mg/day; olanzapine is not indicated for doses exceeding this threshold. 1
Titration Strategy
- Allow at least 1 week between dose adjustments because steady-state plasma concentrations require approximately 7 days in typical patients. 1
- Use 5 mg increments or decrements when dosage changes are necessary. 1
- Increase to >10 mg/day only after clinical assessment confirms inadequate response at the target dose; doses of 15 mg/day or greater should be reserved for patients who clearly require higher exposure. 1
Special Populations Requiring Lower Starting Doses
Elderly, Debilitated, or Pharmacodynamically Sensitive Patients
- Start at 5 mg once daily in patients who are debilitated, have a predisposition to hypotensive reactions, or exhibit factors that slow olanzapine metabolism (e.g., nonsmoking females ≥65 years). 1
- Escalate dose with caution in these populations, as they are more sensitive to olanzapine's pharmacodynamic effects. 1
Hepatic or Renal Impairment
- Moderate hepatic or renal impairment calls for control of serum levels to maximize safety; therapeutic drug monitoring (TDM) is recommended in these patients. 2
- Optimal therapeutic serum range is 20–40 ng/mL; concentrations ≥80 ng/mL are associated with increased adverse events. 2
Adolescents (Ages 13–17) with Schizophrenia
- Start with 2.5 or 5 mg once daily, with a target dose of 10 mg/day. 1
- Titrate in 2.5 or 5 mg increments when adjustments are needed; the mean modal dose in adolescent trials was 12.5 mg/day (mean 11.1 mg/day). 1
- Maximum dose is 20 mg/day; safety and efficacy above this dose have not been established in adolescents. 1
Accelerated Titration for Acute Agitation
- In acutely agitated patients with schizophrenia, start olanzapine 10 mg/day and consider increasing to 20 mg/day as early as day 3 if clinically indicated. 3
- Adjunctive lorazepam (up to 12 mg/day as needed) provides superior acute agitation control compared to olanzapine alone; the combination achieves faster sedation than either agent alone. 3
- Significant within-group improvement in agitation scores occurs as early as 1 hour after initiating olanzapine plus lorazepam. 3
Maintenance Treatment
- Continue olanzapine at 10–20 mg/day for maintenance therapy in patients who have stabilized on the medication for approximately 8 weeks. 1
- Periodically reevaluate long-term necessity of olanzapine for each individual patient during extended treatment. 1
Dosing Considerations Based on Metabolic Factors
Smoking Status
- Smoking induces CYP1A2 and decreases olanzapine serum levels; smokers may require higher doses to achieve therapeutic concentrations. 2
Drug Interactions
- Carbamazepine induces CYP450 enzymes and lowers olanzapine levels; dose adjustment may be necessary. 2
- Fluvoxamine inhibits CYP1A2 and increases olanzapine concentrations; dose reduction may be required. 2
- Clinically relevant CYP2D6 inhibition was observed only when combined with additional factors such as female gender or advanced age. 2
Therapeutic Drug Monitoring (TDM)
- Optimal therapeutic serum range is 20–40 ng/mL; titrating patients to this range augments response while minimizing side effects. 2
- Serum concentrations ≥80 ng/mL are the threshold for adverse events; however, postmortem levels are higher than antemortem levels. 2
- TDM is recommended for patients with hepatic or renal impairment, suspected non-adherence, or inadequate response at standard doses. 2
Common Pitfalls to Avoid
- Do not escalate above 10 mg/day without clear clinical justification, as higher doses rarely improve efficacy and increase extrapyramidal symptoms and metabolic side effects. 1, 4
- Do not increase doses more frequently than weekly intervals, as steady-state is not achieved until approximately 7 days. 1
- Do not exceed 20 mg/day in routine clinical practice; doses of 30–40 mg/day are not FDA-approved and carry higher risk of akathisia, particularly in patients with a history of extrapyramidal symptoms. 1, 5
- Avoid underdosing in smokers or patients on enzyme-inducing medications, as subtherapeutic levels may result in treatment failure. 2
Baseline and Ongoing Monitoring
- Obtain baseline metabolic parameters including BMI, waist circumference, blood pressure, fasting glucose, and fasting lipid panel before starting olanzapine. 6
- Monitor BMI monthly for 3 months, then quarterly; reassess blood pressure, fasting glucose, and lipids at 3 months and annually thereafter. 6
- Weight gain is the most common adverse effect; proactive dietary counseling and exercise recommendations should begin at treatment initiation. 6
Alternative Formulations
- Olanzapine long-acting injection (LAI) provides sustained plasma concentrations with dosing intervals ≤4 weeks; doses of 150 or 300 mg every 2 weeks and 210 or 405 mg every 4 weeks provide steady-state concentrations similar to oral 5–20 mg/day. 7
- LAI should be considered only after acute stabilization on oral olanzapine, typically after 4–6 weeks of symptom control. 7